FMP
Enter
API Tools
Extras
Protagenic Therapeutics, Inc.
PTIX
NASDAQ
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
0.3 USD
0.0412 (13.73%)
Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
-
-
-
-
-
-
-
-
-
-
Revenue %
-
-
-
-
-
-
-
-
-
Operating Cash Flow
-1.35M
-2.8M
-1.99M
-3.7M
-4.22M
-
-
-
-
-
Operating Cash Flow %
100
100
100
100
100
100
100
100
100
Cap Ex
-
-
-1.8k
-149.78k
-
-
-
-
-
-
Cap Ex %
100
100
100
100
100
-
-
-
-
Free Cash Flow
-1.35M
-2.8M
-2M
-3.85M
-4.22M
-
-
-
-
-
